1. Medtech Insight
  2. >>Business
  3. >>Strategy

GTCR Dips into Devices with Devicor

GTCR Golder Rauner invests $250 million in Devicor Medical Products LLC, its first investment in the medical device industry.

Private equity firm GTCR Golder Rauner LLC has spent the past decade building pharmaceutical and health care services companies, sometimes from scratch, sometimes jumping in as a hefty financial backer. The firm scored some successes, the most notable and recent being the announced sale of Lundbeck Inc. for a possible purchase price of $900 million. [See Deal] Such a price tag would deliver old-school venture returns to the Chicago-based PE firm, at a time when venture capital firms can't deliver such returns. Despite successes in the pharmaceutical and health care services industries, GTCR has steered clear of the medical device industry.

It was nothing personal. GTCR long recognized the opportunity medical devices presented as a sort of third leg to its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

PathAI Expands AISight Dx Label With PCCP-Guided Addition Of Roche Scanners

 
• By Natasha Barrow

Roche’s scanners have been integrated with PathAI’s AISight Dx system. The system’s FDA-cleared PCCP allows new components to be validated and integrated without additional FDA clearance. Eric Walk, chief medical officer, hints at future biopharma companion diagnostic collaborations.

Monogram Sets Sept. 30 Shareholder Vote on $177M Zimmer Biomet Deal, $11M Fee If Terminated

 
• By Shubham Singh

Under the deal, Monogram shareholders will receive $4.04 per share in cash, plus a contingent value right (CVR) that could deliver up to $12.37 per share in additional payments if milestone targets are achieved by 2030.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 
• By Natasha Barrow

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

More from Business

Highridge Medical CEO Whitney On Accelus Buys And Spine Strategy

 
• By Ashley Yeo

After divesting bone healing products in mid-year, Highridge Medical doubled down on its spine capabilities with a triple purchase of technologies from Accelus, bringing access to “Adaptive Geometry.” CEO Rebecca Whitney explained Highridge’s strategy.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Abbott’s Navitor TAVR Wins CE Mark Expansion, New Guidelines Allow Treatment For Younger Patients

 
• By Marion Webb

Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.